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ABSTRACT The Epstein-Barr virus (EBV) BILF1 gene encodes a constitutively active
G protein-coupled receptor (GPCR) that downregulates major histocompatibility
complex (MHC) class I and induces signaling-dependent tumorigenesis. Different
BILF1 homologs display highly conserved extracellular loops (ECLs) including the
conserved cysteine residues involved in disulﬁde bridges present in class A GPCRs
(GPCR bridge between transmembrane helix 3 [TM-3] and ECL-2) and in chemokine
receptors (CKR bridge between the N terminus and ECL-3). In order to investigate
the roles of the conserved residues in the receptor functions, 25 mutations were cre-
ated in the extracellular domains. Luciferase reporter assays and ﬂow cytometry
were used to investigate the G protein signaling and MHC class I downregulation in
HEK293 cells. We ﬁnd that the cysteine residues involved in the GPCR bridge are im-
portant for both signaling and MHC class I downregulation, whereas the cysteine
residues in the N terminus and ECL-3 are dispensable for signaling but important for
MHC class I downregulation. Multiple conserved residues in the extracellular regions
are important for the receptor-induced MHC class I downregulation, but not for sig-
naling, indicating distinct structural requirements for these two functions. In an engi-
neered receptor containing a binding site for Zn2 ions in a complex with an aro-
matic chelator (phenanthroline or bipyridine), a ligand-driven inhibition of both the
receptor signaling and MHC class I downregulation was observed. Taken together,
this suggests that distinct regions in EBV-BILF1 can be pharmacologically targeted to
inhibit the signaling-mediated tumorigenesis and interfere with the MHC class I
downregulation.
IMPORTANCE G protein-coupled receptors constitute the largest family of mem-
brane proteins. As targets of 30% of the FDA-approved drugs, they are valu-
able for drug discovery. The receptor is composed of seven membrane-spanning
helices and intracellular and extracellular domains. BILF1 is a receptor encoded
by Epstein-Barr virus (EBV), which evades the host immune system by various
strategies. BILF1 facilitates the virus immune evasion by downregulating MHC
class I and is capable of inducing signaling-mediated tumorigenesis. BILF1 ho-
mologs from primate viruses show highly conserved extracellular domains. Here,
we show that conserved residues in the extracellular domains of EBV-BILF1 are
important for downregulating MHC class I and that the receptor signaling and
immune evasion can be inhibited by drug-like small molecules. This suggests
that BILF1 could be a target to inhibit the signaling-mediated tumorigenesis and
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interfere with the MHC class I downregulation, thereby facilitating virus recogni-
tion by the immune system.
KEYWORDS EBV-BILF1, Epstein-Barr virus, GPCR, major histocompatibility complex,
signaling, tumor immunology
Epstein-Barr virus (EBV) infects90% of adults worldwide (1–3). The virus is classiﬁedas a gamma 1 gammaherpesvirus in genus Lymphocryptovirus (LCV) and forms
latent infection in B cells after the establishment of a balance between host immune
response and virus immune evasion strategies. The virus is associated with growth-
transforming activity in human B cells resulting in different types of cancers (4–6). In
order to succeed in efﬁcient immune evasion and establish a lifelong infection, EBV
genes encode a number of immunoevasins, some of which target the major histocom-
patibility complex (MHC) class I molecules, including BGLF5 and BNLF2a. The virus is
normally kept under T cell surveillance, yet the immunoevasins compromise the
elimination of the EBV-transformed cells, thereby contributing to malignancies associ-
ated with EBV infection (4, 5, 7–9). Among these EBV-encoded immunoevasins is BILF1,
a viral gene encoding a G protein-coupled receptor (GPCR). Several functions have
been shown for herpesvirus-encoded GPCRs (vGPCRs) including chemokine scaveng-
ing, cell migration stimulation, and intracellular signaling reprogramming (2, 10). These
genes are believed to be captured through molecular piracy during coevolution of the
virus with the respective host (11–13).
The EBV-encoded BILF1 receptor downregulates MHC class I and induces signaling-
mediated tumorigenesis both in vitro and in vivo (14–17). It signals constitutively via
Gi, where it modulates cyclic AMP (cAMP) response element (CRE) activation (18, 19).
This constitutive activity is shared with other virus-encoded receptors such as US28
(human cytomegalovirus [HCMV]) and ORF74 (human herpesvirus 8 [HHV8]), both of
which also induce signaling-mediated tumorigenesis (10, 13, 20–22). Unlike these
vGPCRs, BILF1 has a unique immunomodulatory function, where it downregulates MHC
class I surface expression (15–17), which causes marked impairment of T cell recogni-
tion (16, 17). BILF1 is a late lytic EBV protein (8). Its immunosuppressive activity
increases as the lytic cycle of EBV progresses and it predominantly inhibits T cell
recognition at the late phase of the virus lytic cycle (8). BILF1 expression has also been
detected at low levels during latency in Burkitt’s lymphoma cell lines (23). Moreover, it
has been detected in EBV-transformed B cell lines (8, 23).
Sequence alignment of 21 BILF1 homologs (15 closely related primate gamma 1
gammaherpesvirus-encoded BILF1 sequences and 6 sequences from the ungulate
gammaherpesviruses) revealed a high degree of conservation among the extracellular
loops (ECLs), especially ECL-2 (24). Among the conserved residues were the cysteine
residues believed to be involved in the GPCR and chemokine characteristic disulﬁde
bridge (24).
GPCRs are targets of more than 30% of marketed drugs with orphan receptors
representing great opportunities in the treatment of many diseases (25). Nearly 400
small molecules are currently being investigated as active therapeutics for around 100
human GPCRs (25). Metal ion site engineering in GPCRs has been used as a tool for
decades to study helical connectivity and provide knowledge about distance con-
straints and conformational changes in GPCRs. This strategy was ﬁrst implemented in
1995, when Elling et al. (26) reported the conversion of the antagonist binding site in
the human tachykinin NK1 receptor to a high-afﬁnity metal ion binding site by
substituting the antagonist binding site with histidine residues. Several studies fol-
lowed using metal ion site engineering to probe putative binding pockets for small
molecules in GPCRs (27–34). The BILF1 receptor does not resemble any other GPCR, and
therefore, current X-ray and Cryo-EM structures are not applicable for building homol-
ogy models. The metal ion site engineering in BILF1 is therefore a valuable strategy to
predict a putative ligand binding pocket in the receptor. BILF1 signaling activity has
been linked to tumor formation, and it was therefore suggested as a potential drug
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target against virus-induced cancers through receptor signaling inhibition by small-
molecule antagonists or inverse agonists (14). In the current study, we aimed to
investigate the possibility of targeting the BILF1 receptor using small molecules in order
to modulate both its signaling and immune evasion functions. We used different
approaches to investigate sequence elements and predict helical connectivity of the
receptor. On the basis of amino acid residue conservation, we created and character-
ized 25 EBV-BILF1 extracellular domain mutants in terms of MHC class I downregulation
and signaling. We also engineered the receptor to contain a binding site for small
‘‘model’’ compounds, the metal ion chelators (32–34). We tested the aromatic chelators
bipyridine and phenanthroline, in a complex with Zn2, for their ability to modulate
receptor signaling and MHC class I downregulation.
RESULTS
BILF1 is an immune evasion gene that modulates the immune system by down-
regulating MHC class I via the endocytic pathway, where MHC class I is targeted for
internalization and the exocytic pathway, where it inhibits the appearance of newly
synthesized MHC molecules at the cell surface (16, 17) (Fig. 1A). We have previously
described a high degree of conservation among the ECLs of BILF1 receptors, especially
ECL-2 (24). In order to investigate the roles of these conserved residues in the receptor-
induced signaling and MHC class I downregulation, we generated 24 point mutations
in the EBV-BILF1 extracellular domain and a mutant, where the ﬁrst 17 residues of the
receptor N terminus were deleted (Δ17-N-term) (Fig. 1B). A total of 25 EBV-BILF1
mutants were generated in the current study and investigated for surface expression,
G protein-mediated signaling, and MHC class I downregulation in HEK293 cells (Fig. 1B).
Impact of conserved cysteine residues in extracellular receptor regions of
EBV-BILF1. The GPCR characteristic disulﬁde bridge (GPCR bridge) between the con-
served cysteine residues of TM-3 and ECL-2 is a common structural feature among
GPCRs (35). EBV-BILF1 displays two cysteine residues in position 97 (C97) at the top of
transmembrane helix 3 (TM-3) and in position 174 (C174) in ECL-2 (Fig. 2A, red; Fig. 1B,
black). These residues are conserved among BILF1 receptors (24) (Fig. 2A, red). We
investigated the impact of these two residues on the receptor functions. To this end,
both residues were mutated to alanine (C97A and C174A), and their surface expression
and signaling were investigated. Both mutants showed reduced surface expression
measured by surface ELISA against the N-terminally attached HA tag with expression of
30% (C97A) and 10% (C174A) of that of wild-type (wt) EBV-BILF1 (Fig. 2B). ELISA and
ﬂow cytometry are commonly used techniques to measure the surface expression,
internalization, and recycling of GPCRs (24, 36–39).
The Gi signaling activity was investigated through their ability to modulate the
forskolin-induced CRE. Forskolin activates adenylate cyclase (AC), which induces cAMP
formation that will result in the downstream activation of CRE, which is inhibited by
Gi-coupled receptors (EBV-BILF1 in this case). The C97A and C174A mutants could not
inhibit the forskolin-induced CRE compared to wt EBV-BILF1, indicating an abolished
Gi signaling activity (Fig. 2C). This phenotype was conﬁrmed by cotransfection with
Gqi4myr in CRE-luciferase assay (see Fig. S1A in the supplemental material). Gqi4myr
provides Gi coupling/Gq signaling system, activating CRE through phospholipase C
(PLC). In other words, the Gi-coupled BILF1 receptor recognizes this chimeric protein
as a Gi, but it functions as Gq subunit. Both mutants did not activate CRE in
Gqi4myr-cotransfected HEK293 cells (Fig. S1A).
EBV-BILF1 displays two additional cysteine residues in the N terminus (C28) and
ECL-3 (C258) (Fig. 2A, blue; Fig. 1B, black). These residues are conserved among BILF1
receptors (24) (Fig. 2A, blue). We investigated the roles of these two residues in receptor
signaling and surface expression. The two residues were mutated to alanine. The
mutants showed reduced surface expression of 25% (C28A) and 12% (C258A) of that
of wt EBV-BILF1 (Fig. 2B). However, both mutants retained a wt-like Gi signaling
activity (Fig. 2D), which was conﬁrmed by the induction of CRE in Gqi4myr-
cotransfected HEK293 cells (Fig. S1B). This suggests that low receptor expression per se
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does not result in low signaling and that these two cysteine residues are not important
for the receptor signaling.
Roles of conserved residues in extracellular BILF1 regions. In order to investigate
the roles of other BILF1 extracellular domain conserved residues (Fig. 3A) in receptor
signaling and surface expression, we created 20 point mutations (Fig. 1B) located in
ECL-1 (3 mutations [Fig. 1B, yellow]), ECL-2 (13 mutations [Fig. 1B, blue]), and ECL-3 (4
mutations [Fig. 1B, green]), and an N-terminal deletion (Fig. 1B, gray). These residues are
marked with red boxes in Fig. 3A. Alanine was introduced in those conserved positions
FIG 1 Model of EBV-BILF1 and its role in MHC class I downregulation. (A) In the endocytic pathway, EBV-BILF1 physically
associates with MHC class I at the cell surface and enhances MHC class I internalization. In the exocytic pathway, EBV-BILF1
inhibits the appearance of newly synthesized MHC class I at the cell surface. EC, extracellular; IC, intracellular. (B) Serpentine
diagram of EBV-BILF1, showing the conserved amino acids in yellow in ECL-1, in blue in ECL-2, and in green in ECL-3
(mutated to alanine in this study). The four conserved cysteine residues (mutated to alanine in this study) are shown in
black. The putative GPCR bridge is shown in red, and the chemokine receptor bridge (CKR bridge) is shown as a blue dotted
line. The N-terminal residues that were deleted in this study to create the mutant Δ17-N-term are shown in gray. The
DRY-like EKT signaling motif is marked by a black box at the bottom of TM-3.
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in the ECLs, and the ﬁrst 17 residues of the EBV-BILF1 N terminus (Δ17-N-term) were
deleted (Fig. 1B and 3A). The surface expression measured by ELISA and signaling of all
these mutants are shown in Fig. 3 and Fig. S2. The mutants showed differential
expression levels (Fig. 3B). In ECL-2a, L167A, R169A, and P171A mutants showed a
wt-like surface expression level, whereas two mutants, mutants with N172A and R175A
located in a closer proximity to the conserved cysteine (C174), showed lower expression
than wt EBV-BILF1 did (Fig. 3B). The mutants with Q89A and E90A in ECL-1 and Y266A
in ECL-3 also showed reduced expression. In contrast, the deletion of the N terminus
residues (Δ17-N-term), removing the positive charge (K86A) in ECL-1 and substituting
E176 and P178 in ECL-2b by alanine resulted in higher surface expression than that for
wt EBV-BILF1 (Fig. 3B). The Gi signaling activity for all the mutants was retained
(Fig. 3C to G). Three mutants, Δ17-N-term, K86A, and P178A mutants, showed even
FIG 2 Sequence alignment of different BILF1 homologs and expression and signaling of EBV-BILF1 mutants without disulﬁde bridges. (A) Fifteen primate BILF1
receptors were aligned using MAFFT (Geneious 7). The sequences show four domains of BILF1, the N terminus (N-term), transmembrane 3 (TM-3), and
extracellular loops 2 (ECL-2) and 3 (ECL-3). The cysteine residues involved in the formation of the GPCR bridge are shown in red boxes. The cysteine residues
involved in the formation of the CKR bridge are shown in blue boxes. (B) ELISA showing the cell surface expression level of four cysteine mutants (C28A, C97A,
C174A, and C258A). HEK293 cells were transiently transfected with 15 ng of N-terminally HA-tagged receptor in the pCMV-HA vector. One day after transfection,
the cells were ﬁxed in 4% paraformaldehyde and incubated with the antibodies. The optical density (OD) was measured at 450 nm, and the data were
normalized to empty vector (0%) and wild-type (Wt) BILF1 (100%) and analyzed by the paired Student t test. Values that are signiﬁcantly different (P 0.0001)
from the value from the Wt BILF1 are indicated by four asterisks. (C and D) Gi signaling activity in HEK293 cells cotransfected with receptor/empty vector DNA,
pFR-Luc transactivator plasmid, or pFA2-CRE transreporter plasmid. Twenty-four hours after transfection, the cells were induced with forskolin (15 M) for 5 h
to activate CRE (via adenylate cyclase activation). (C) Cells transfected with different concentrations of C97A (open squares), C174A (closed triangles), empty
pCMV-HA vector (open circles), or wt BILF1 (closed circles) plasmid DNA. The GPCR bridge between the two cysteine residues C97 (TM-3) and C174 (ECL-2) is
shown in red. (D) Cells transiently transfected with different concentrations of C258A (open squares), C28A (closed triangles), empty pCMV-HA vector (open
circles) or wt BILF1 (closed circles) plasmid DNA. The CKR bridge between the two cysteine residues C28 (N-term) and C258 (ECL-3) is shown in blue. The ﬁgure
is from 3 independent experiments normalized to the values in the absence of forskolin (0%) and maximum activity (100%). Error bars represent standard errors
of the means (SEM). The error bars for wt BILF1 in panel C were smaller than the symbols and are therefore not visible.
EBV-BILF1 Extracellular Domains ®
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higher activity compared to wt EBV-BILF1 at low DNA concentrations (Fig. 3C, D, and F),
whereas two mutants, E90A and R169A mutants, showed reduced signaling activity
compared to wt EBV-BILF1 (Fig. 3D and E). Figure 3 shows the surface expression and
signaling of 12 mutants; the rest (9 mutants) are shown in Fig. S2. The Gi signaling
activity of the mutants displayed in Fig. 3 and Fig. S2 was conﬁrmed by cotransfection
of Gqi4myr in CRE-luciferase assay (Fig. S3).
Impaired MHC class I downregulation upon removal of the conserved residues
in extracellular BILF1 regions. We then proceeded with the investigation of the MHC
FIG 3 Sequence alignment of different BILF1 homologs and expression and signaling of different EBV-BILF1 extracellular domain mutants. (A) The sequences
were created as described in the legend to Fig. 2A. The sequences show the different regions of the BILF1 extracellular domain, the N terminus (N-term; gray)
and extracellular loops 1 (ECL-1; yellow), 2 (ECL-2; blue), and 3 (ECL-3; green). Conserved amino acids (mutated to alanine in the current study) are shown in
red boxes. The N-terminus deletion mutant (Δ17-N-term) is shown in light gray in a red box. (B) ELISA showing the cell surface expression level as in Fig. 2.
(C to G) Gi signaling as in Fig. 2. HEK293 cells were transfected with a concentration range of 1 to 10 ng of N-terminally HA-tagged receptor in the pCMV-HA
vector. Error bars represent standard errors of the means (SEM) for 3 or 4 independent experiments normalized to the values in the absence of forskolin (0%)
and maximum activity (100%). Values that were signiﬁcantly different by the paired Student t test are indicated by asterisks as follows: *, P 0.05; **, P 0.01;
***, P 0.001; ****, P 0.0001. The errors bars were smaller than the symbols in some of the ﬁgures and are therefore not visible.
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class I downregulation function of the mutants displayed in Fig. 2 (4 mutants) and Fig. 3
(12 mutants) using ﬂow cytometry (Fig. 4A). These mutants were selected based on
their degree of conservation, position in the receptor, and their signaling and expres-
sion patterns. A representative experiment for MHC class I downregulation is shown in
Fig. 4A, while Fig. 4B shows the values quantiﬁed from ﬁve independent experiments.
Consistent with what has previously been shown (16, 17), wt EBV-BILF1 induced 50%
reduction in the cell surface level of MHC class I relative to cells transfected with empty
vector (Fig. 4A and B). The cysteine mutants C97A, C174A, C28A, and C258A showed
impaired MHC class I downregulation, where they reduced MHC class I surface level by
20% (Fig. 4A and B). The Δ17-N-term, P171A, R175A, E176A, and P178A mutants
induced a wt-like level of MHC class I downregulation (Fig. 4A and B). The K86A and
R169A mutants induced a slightly, but reproducibly higher MHC class I downregulation
than wt EBV-BILF1, where they reduced MHC class I surface level by 60% (Fig. 4A and
B). The mutants E90A and N172A resulted in 40% reduction of MHC class I surface
level (Fig. 4A and B). The Q89A, L167A, and Y266A mutants showed impaired MHC class
I downregulation and reduced MHC class I surface level by only 20% (Fig. 4A and B).
These results indicate that various conserved residues at the receptor extracellular
domain are important for the EBV-BILF1-induced surface MHC class I downregulation.
MHC class I downregulation is correlated with EBV-BILF1 surface expression,
but not signaling activity. EBV-BILF1 has been suggested to physically associate with
the MHC class I molecules at the cell surface with further internalization of the
molecules (17). We used ﬂow cytometry to measure the surface expression of the
receptor mutants (Fig. 4C) along with the MHC class I surface level in HEK293 cells
expressing different BILF1 mutants. Both the surface expression and MHC class I
downregulation of the mutants were correlated with r2 0.5 (Fig. 4D). The only mutant
whose MHC class I downregulation was not correlated with its surface expression was
the Δ17-N-term mutant (Fig. 4B to D). This mutant showed a wt-like level of MHC class
I downregulation (Fig. 4A and B), but its surface expression measured by ﬂow cytometry
(Fig. 4C) was reduced relative to the wt. This could be because of improper folding of
the N-terminally attached HA tag of the receptor mutant in the pCDNA3-IRES-nlsGFP
and not pCMV-HA expression vector (see surface ELISA [Fig. 3B]). These results suggest
that the receptor surface expression is important for the MHC class I downregulation
function and implies a physical association between the receptor and MHC class I
molecules at the cell surface as previously suggested (17).
BILF1 signaling activity, which has been shown to be related to the receptor-induced
tumorigenesis (14), has not been consistently correlated with the receptor-induced
MHC class I downregulation (16, 17). A possible link between these two functions was
investigated in the current study. The Δ17-N-term, K86A, E90A, C97A, P171A, C174A,
R175A, E176A, and P178A mutants showed correlated signaling and MHC class I
downregulation functions (Fig. 4E), where Δ17-N-term, K86A, P171A, R175A, E176A, and
P178A mutants retained a wt-like signaling and MHC class I downregulation functions
(Fig. 4E). The E90A mutant, whose signaling activity was reduced also showed reduced
MHC class I downregulation relative to the wt. Both the signaling activity and MHC class
I downregulation functions of the C97A and C174A mutants were impaired (Fig. 4E).
However, the C28A, Q89A, L167A, R169A, N172A, C258A, and Y266A mutants showed
discordant signaling and MHC class I downregulation functions, where C28A, Q89A,
L167A, C258A, and Y266A mutants that retained a wt-like signaling showed impaired
MHC class I downregulation (Fig. 4E). In contrast, the R169A mutant, which showed
reduced signaling activity (Fig. 3E and Fig. 4E), showed increased downregulation of
MHC class I surface level by 60% compared to 50% for wt EBV-BILF1 (Fig. 4A and B). On
the other hand, the N172A mutant retained a wt-like signaling and showed reduced
MHC class I downregulation (Fig. 4E) relative to the wt. These results indicate that
EBV-BILF1-induced MHC class I downregulation is not necessarily dependent on the
signaling function of the receptor.
EBV-BILF1-mediated functions can be inhibited by aromatic metal ion chela-
tors. No ligands have been identiﬁed for EBV-BILF1, whose signaling activity has been
EBV-BILF1 Extracellular Domains ®
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FIG 4 Flow cytometry showing MHC class I downregulation by different EBV-BILF1 mutants and its correlation with signaling and surface expression. (A)
Histograms for the MHC class I downregulation by EBV-BILF1 mutants. HEK293T cells were transiently transfected with 1 g of pcDNA3-HABILF1-IRES-nlsGFP
(Continued on next page)
Fares et al. ®
January/February 2019 Volume 10 Issue 1 e01707-18 mbio.asm.org 8
 o
n
 M
arch 5, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
linked to tumor formation (14). In order to investigate the possibility of the manipu-
lation of the (i) receptor signaling activity or (ii) MHC class I downregulation function by
small molecules, we created an artiﬁcial binding site in the receptor by introducing
histidine (H) in position 105 (3.33 using the Ballesteros-Weinstein nomenclature [40])
and aspartic acid (D) in position 268 (7.50) to generate the F105H P268D double mutant
EBV-BILF1 (Fig. 5A). The effects of the metal ion chelators (phenanthroline or bipyridine
in a complex with Zn2, referred to here as ZnPhe and ZnBip, respectively [Fig. 5B]) on
the Gi signaling activity of the mutant compared to wt EBV-BILF1 were investigated in
an inositol phosphate (IP3) accumulation assay in HEK293 cells cotransfected with
Gqi4myr. In wt EBV-BILF1, none of the ligands altered the basal activity of the receptor
(Fig. 5C and D). In the F105H P268D double mutant, ZnPhe and ZnBip inhibited the
basal activity with an EC50 of 1 and 2 M, respectively, indicating inverse agonism
activity of the metal chelators (Fig. 5C and D). Both ligands inhibited the receptor
FIG 4 Legend (Continued)
(solid black line) or empty pcDNA-IRES-nlsGFP vector (broken black line). Forty-eight hours posttransfection, the cells were harvested and analyzed by ﬂow
cytometry. The isotype control staining is shown in gray. The cells were gated at high GFP and high HA expression. (B) Bar charts showing the MHC class I
downregulation by the EBV-BILF1 mutants shown in Fig. 4A, normalized to the mean anti-MHC class I ﬂuorescence index of the empty vector. (C) Surface
expression level measured by mean anti-HA ﬂuorescence index and normalized to the vector (0%) and wild-type (Wt) BILF1 (100%). (D) Correlation between
the EBV-BILF1 receptor surface expression and MHC class I surface level. (E) Signaling and MHC class I downregulation activity depicted in pairs. The black bars
show the signaling activity of 2.5 ng DNA concentration normalized to the vector (100%) and wt BILF1 (0%), The red bars show the MHC class I downregulation
normalized as in panel B. Error bars represent SEM of 3 independent experiments analyzed by the paired Student t test (*, P 0.05; **, P 0.01).
FIG 5 Effects of Zn2 chelators on the signaling activity and expression of wt EBV-BILF1 and the F105H P268D double mutant EBV-BILF1. (A) Wheel diagram
for EBV-BILF1 showing the F105H P268D double mutant. (B) Structure of phenanthroline (Phe) or bibyridine (Bip) in a complex with Zn2 (ZnPhe and ZnBip).
(C and D) IP3 accumulation in HEK293 cells cotransfected with wt pcDNA3-HABILF1-IRES-nlsGFP (closed circles) or the F105H P268D double mutant EBV-BILF1
(open circles) and Gqi4myr, in the presence of ZnPhe (C) or ZnBip (D). The data in panels C and D were normalized to zero and maximum IP3 accumulation
after background subtraction. (E and F) Surface expression level measured by mean anti-HA ﬂuorescence index of wt BILF1 (black bars) or F105H P268D mutant
(open bars) in the presence of ZnPhe (E) or ZnBip (F). The data in panels E and F were normalized to the values in the absence of the metal chelator. Error bars
represent SEM from three independent experiments analyzed by the unpaired Student t test. Statistical signiﬁcance is indicated as follows: *, P 0.05; **,
P 0.01; ****, P 0.0001; ns, not signiﬁcant.
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activity to a submaximal level (30%), and the level of activity depended on complex
formation between Zn2 and the aromatic chelators as shown in Fig. S4, where no
difference was observed between the signaling activity of the wt and F105H P268D
double mutant EBV-BILF1 by ZnCl2. Moreover, both ZnPhe and ZnBip increased the
F105H P268D double mutant EBV-BILF1 surface expression by 40% and 30%, respec-
tively, at the highest concentration of the metal chelator (Fig. 5E and F), whereas the
effect on wt EBV-BILF1 expression was modest for ZnBip (15% at 10 M) and absent
for ZnPhe (Fig. 5E and F).
The effects of the chelators were further extended to the MHC class I downregula-
tion function of the F105H P268D double mutant EBV-BILF1 compared to wt EBV-BILF1
(Fig. 6), where different concentrations (1, 10, and 100 M) of the ligands were
assessed. Both ligands slightly inhibited the MHC class I downregulation function of wt
BILF1 (Fig. 6A and B) with 10% higher (from 40% to 50%) MHC class I surface level
relative to that in the absence of ligands (Fig. 6B). The ligands inhibited the MHC class
I downregulation function of the F105H P268D double mutant EBV-BILF1 (Fig. 6C and
D) with 15% higher (from 60% to 75%) MHC class I surface expression relative to the
level in the absence of ligands (Fig. 6D).
DISCUSSION
GPCRs possess highly diverse extracellular domains responsible for binding diverse
ligands and more conserved transmembrane and intracellular domains responsible for
signal transduction and binding/activating G protein and arrestins (41, 42). Interest-
ingly, BILF1 receptors of different gammaherpesviruses display a high degree of
conservation among the ECLs, a level of conservation that exceeds that of the TM
region (24). In this study, we aimed to investigate the roles of the conserved residues
in the EBV-BILF1 extracellular domain in relation to both receptor-mediated signaling
and MHC class I downregulation, given the high degree of conservation and general
FIG 6 Flow cytometry showing the effects of Zn2 chelators on the MHC class I downregulation of wt EBV-BILF1 and the F105H P268D double mutant
EBV-BILF1. (A to D) MHC class I downregulation by wt BILF1 and F105H P268D double mutant. (A and C) Histograms for the MHC class I downregulation in cells
transected with wt BILF1 (A) and F105H P268D double mutant. The transfected cells were treated with ZnPhe and ZnBip. HEK293T cells were transiently
transfected with 1 g of pcDNA3-HABILF1-IRES-nlsGFP (solid black line), empty pcDNA-IRES-nlsGFP vector (broken black line). At 24 h posttransfection, the
metal chelators were added. At 48 h posttransfection, the cells were harvested, stained, and analyzed by ﬂow cytometry. The isotype control staining is shown
in gray. The cells were gated at high GFP and high HA expression. (B and D) Bar charts showing the MHC class I downregulation in cells transfected with wt
BILF1 (B) and F105H P268D double mutant (D and treated with 10 M ZnPhe or 100 M ZnBip. Error bars represent SEM from ﬁve independent experiments
normalized to vector with and without the chelators and analyzed by the unpaired Student t test (ns, not signiﬁcant; *, P 0.05).
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involvement of the extracellular receptor domains in ligand binding. We also investi-
gated the susceptibility of EBV-BILF1 signaling and MHC class I downregulation func-
tions to inhibition by small-molecule ligands. Doing this we are providing the ﬁrst
evidence that EBV-BILF1 is a promising drug target for interference with BILF1/MHC
class I interaction facilitating antigen presentation of MHC class I/peptide targets to T
cells, which would facilitate virus recognition.
Disulﬁde bridges, constitutive signaling, and MHC class I downregulation.
Disulﬁde bridges in the GPCR extracellular domain are important for maintained
receptor structure and function (33, 43, 44). The disulﬁde bridge between TM-3 and
ECL-2 is a common structural feature among class A GPCRs and present in about 90%
of the receptors (44, 45). Several studies have shown that a disruption of this bridge
results in impaired ligand binding and reduced ligand-dependent signaling (33, 43, 44,
46, 47). In addition, disrupting this bridge disables 90% of the receptors from reaching
the cell surface (33, 48). We obtained similar results, where mutating the conserved
cysteine residues in TM-3 and ECL-2 (possibly involved in GPCR bridge) resulted in
reduced cell surface expression and impaired receptor signaling. We also ﬁnd that these
residues are essential for EBV-BILF1-induced MHC class I downregulation. These obser-
vations imply that EBV-BILF1 shares this structural feature with the rest of class A GPCRs
and that this bridge is important for the structure and function of the receptor.
The extra disulﬁde bridge displayed by chemokine receptors (CKR bridge) provides
extra receptor constraints and regulates receptor function (33, 43, 49). Here, we show
that the cysteine residues possibly involved in a CKR-like bridge formation are dispens-
able for EBV-BILF1-mediated Gi signaling, whereas both residues are important for
receptor-induced MHC class I downregulation. In addition, we found that both residues
were important for maintained receptor cell surface expression. These results imply that
EBV-BILF1 displays the CKR bridge and that this bridge stabilizes the receptor structure
important for MHC class I downregulation and surface expression, but not signaling.
Importance of the extracellular domain in EBV-BILF1-mediated functions. In
2011, a study by Zuo et al. (16) identiﬁed important domains involved in BILF1-induced
MHC class I downregulation; they showed that the DRY-like EKT signaling motif at the
bottom of TM-3 is important for enhanced endocytosis, while the deletion of the
receptor C-terminal domain resulted in impaired lysosomal degradation of MHC class I
molecules. The high degree of conservation among BILF1 extracellular domains (24)
makes it compelling to presume a preserved function, which could be maintaining (i)
the high basal receptor activity, (ii) ligand binding, and/or (iii) interaction with MHC
class I molecules. We therefore created different EBV-BILF1 extracellular domain mu-
tants and investigated their ability to mediate signaling activity and reduce the surface
level of MHC class I. Most of the mutants retained a wt-like signaling activity, which
implies that this function is dependent on the intracellular region of the receptor, as
previously reported for BILF1 (50) and other GPCRs (41, 42). In contrast, removing the
conserved residues in the receptor extracellular domain resulted in an impaired MHC
class I downregulation function of EBV-BILF1. The reduced surface expression of these
mutants (Fig. 5C) indicates that the conserved residues at the extracellular domain
maintain a receptor structure important for the interaction with MHC class I at the cell
surface.
Our results suggest that EBV-BILF1 ECLs are directly or indirectly involved in the
interaction with MHC class I molecules. Intriguingly, in contrast to the impact of Cys28
(in the N terminus) on the receptor immune modulation, deleting the ﬁrst 17 residues
of the EBV-BILF1 N terminus did not affect receptor signaling or MHC class I down-
regulation.
Correlation between BILF1-induced signaling and MHC class I downregulation.
The link between BILF1 signaling and MHC class I downregulation function has not
been consistently described (16, 17). It has been shown that the signaling-deﬁcient
K122A BILF1 mutant retained the ability to downregulate the MHC class I surface
expression level (17). This mutant, which has disrupted EKT (DRY-like) signaling motif
and showed impaired NF-B signaling properties, could reduce MHC class I surface
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levels to an extent similar to that of the wt receptor (17). It was therefore suggested that
these functions are not critically related. Afterwards, it was shown that the K122A
mutant could not mediate MHC class I internalization, and it was therefore suggested
that the EKT motif is necessary for MHC class I-enhanced internalization through a
mechanism that is probably independent of the receptor signaling activity (16). This
goes in line with our ﬁndings, where we show that MHC class I downregulation and
signaling activities are not necessarily dependent. Combined with previous studies (16,
17), our observations imply that the molecular mechanisms of BILF1 function(s) are
complex and that further investigation of the relationship between BILF1 signaling and
MHC class I downregulation properties is warranted.
EBV-BILF1 as a drug target. Metal ion site engineering has traditionally been used
to predict the helical connectivity of GPCRs. This has been ﬁrst described for the
tachykinin NK1 receptor by the introduction of histidine in the non-peptide-binding site
(26) and later for others (27–34). The same strategy has been implemented to describe
helical connectivity of the tumorigenic virus-encoded ORF74-HHV8 receptor (31). Sim-
ilarly, an engineered site for metal ion chelator complexes was created in the CXCR3
receptor by introducing a His residue at the corresponding position for the adrenergic
receptor ligand binding pocket (30).
The fact that EBV-BILF1 does not resemble any of the aforementioned receptors
makes the receptor probe for such compounds challenging. Nevertheless, we success-
fully created an artiﬁcial binding site in EBV-BILF1 through double mutant engineering
between TM-3 and TM-7. Our results raise the enticing prospect of exploiting the
receptor extracellular domains (including the outer transmembrane domain) to inhibit
receptor signaling and interfere with receptor/MHC class I interaction.
MATERIALS AND METHODS
Cell lines and culture and transfection conditions. Dulbecco’s modiﬁed Eagle’s medium (DMEM)
purchased from Invitrogen, Germany, containing 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin (Pen-Strep), was used to grow HEK293 cells at 37°C and 10% CO2. Transient transfection of
HEK293 cells was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions and with CaPO4 (51).
Vector constructs and receptor expression. EBV-BILF1 was cloned into the pCMV-HA vector
(Clontech). The expression plasmid pCDNA3-HABILF1-GFP and control empty vector pCDNA3-IRES-
nlsGFP have been described previously (16, 17). The EBV-BILF1 mutants were generated by QuikChange
PCR using high-ﬁdelity Pfu DNA polymerase. The constructs were veriﬁed by restriction digestion and
sequence analysis.
Antibodies. For enzyme-linked immunosorbent assay (ELISA) experiments, anti-hemagglutinin
monoclonal antibodies (anti-HA MAbs) (anti-H11, clone 16B12, mouse; HISS Diagnostics, Germany) and
goat anti-mouse horseradish peroxidase-conjugated antibody purchased from Dianova, Denmark, were
used. For ﬂow cytometry, phycoerythrin (PE)-conjugated MAb, clone W6/32, (BioLegend, UK) and Alexa
Fluor 647-conjugated anti-HA (Cell Signaling, UK) were used. The antibodies were diluted according to
the manufacturer’s instructions.
Recombinant G protein plasmid (Gqi4myr). Gqi4myr or GΔ6qi4myr is a chimeric Gq subunit in
which 6 amino acid residues at the N terminus were deleted, a myristoylation motif was created at the
N terminus, and the Gi 4 C-terminal residues replaced the corresponding residues in the Gq subunit
(52). The receptor recognizes Gqi4myr as Gi and gives Gq readout (52).
Metal ion chelators. The aromatic chelators, bipyridine (Bip) or phenanthroline (Phe) were made in
a complex with Zn2. ZnCl2 was mixed with either 2,2=-bipyridine or 1,10-phenanthroline (Sigma-Aldrich,
USA) in the 1:2 ratio as previously described (32, 33).
ELISA to measure cell surface expression. The receptor cell surface expression was conﬁrmed by
ELISA conducted as described previously (24). Brieﬂy, HEK293 cells were seeded in 96-well plates at a
density of 2 105 cells/well 24 h prior to transient transfection with N-terminal HA-tagged receptor
cloned in the pCMV vector (15 ng). One day after the cells were seeded, the cells were ﬁxed in 4%
paraformaldehyde, blocked in PBS containing bovine serum albumin (BSA) at room temperature (RT). The
cells were then incubated with the primary antibody for 1 h at RT, while shaking. This was followed by
a washing step and incubation with the secondary antibody for 1 h at RT, while shaking. The activity was
detected by 3,3=-5,5=-tetramethyl benzidine substrate (Kem-En-Tec, Denmark) and the reaction was
stopped with H2SO4. The optical density (OD) was measured at 450 nm.
cAMP response element (CRE) reporter assay. HEK293 cells were transiently transfected 24 h after
the cells were seeded at 2 105 cells/well, with increasing amounts of the receptor/empty vector DNA,
both with 25 ng/well of pFR-Luc transactivator plasmid and 6 ng/well of pFA2-CRE transreporter plasmid
(Stratagene, USA) and 30 ng/well Gqi4myr plasmid DNA (kindly provided by Evi Kostenis, University of
Bonn). A concentration range of 0.5 ng to 10 ng of the receptor and empty expression vector DNA was
used. For forskolin stimulation, no Gqi4myr was added. The cells were treated with 15 M forskolin
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(Sigma, USA) at 24 h posttransfection, and the luciferase activity was measured at 5 h after forskolin
addition.
Inositol trisphosphate (IP3) accumulation. The assay was performed as described previously (24,
51). Brieﬂy, HEK293 cells were transfected with 5 g of BILF1 or empty vector DNA and 5 g of Gqi4myr.
One day after transfection, the cells were seeded in a 96-well plate at 35,000 cells/well in the presence
of 4 Ci of myo-[3H]inositol. One day after the cells were seeded, the cells were incubated with different
concentrations of metal ion chelators in 0.1 ml Hanks’ balanced salt solution (Invitrogen, UK) supple-
mented with 10 mM LiCl at 37°C for 90 min. The cells were then treated as described previously (24) and
measured in a top counter. Brieﬂy, the cells were incubated in formic acid (10 mM) on ice for 30 min. The
extract was transferred to a 96-well plate and incubated with YSi poly-D-lysine-coated beads (PerkinEl-
mer, USA) diluted 1:8 while shaking at maximum speed. The radiation was measured in a Top-Counter.
Flow cytometry to analyze surface MHC class I molecules and receptors. PE-labeled W6/32
antibodies or a PE-labeled isotype control MAb were used to determine the levels of total MHC class I
at HEK293T cell surface. The cells were seeded in 24-well plate 24 h prior to transient transfection with
1 g/well of the N-terminal HA-tagged BILF1 inserted in the pCDNA3-IRES-nlsGFP expression vector.
Forty-eight hours after transfection, the cells were harvested and stained with anti-MHC class I and
anti-HA antibody (detecting the surface level of BILF1). Zombie Red dye (BioLegend, UK) was used to
stain for the live/dead (LD) cells. When the metal ion chelators were used, they were added at different
concentrations at 24 h posttransfection. The samples were analyzed on a BD Accuri C6 instrument. The
data were analyzed using FlowJo (TreeStar) and BD Accuri C6 software.
Data analysis and statistics. The data were analyzed with GraphPad Prism, FlowJo (TreeStar), and
BD Accuri C6 software and expressed as means  standard errors of the means (SEM). Statistical analysis
was performed in GraphPad Prism. Speciﬁc tests are noted in the ﬁgure legends. P values of  0.05 were
considered statistically signiﬁcant.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.01707-18.
FIG S1, PDF ﬁle, 0.8 MB.
FIG S2, PDF ﬁle, 0.8 MB.
FIG S3, PDF ﬁle, 1 MB.
FIG S4, PDF ﬁle, 0.8 MB.
ACKNOWLEDGMENTS
This study was funded by the Faculty of Health and Medical Sciences, The Novo-
Nordisk Foundation, A. P. Møller Foundation, and European Research Council. K.S. was
funded by a postdoc grant from the Danish Council for Independent Research.
S.F. designed the research study, conducted the experiments, analyzed the data, and
wrote the manuscript. K.S. designed the research study, revised the manuscript, and
contributed to data analysis. E.T.B.O. and S.J. contributed to the experimental work
and data analysis. J.Z. and T.N.K. contributed to the research study. M.R.W. designed the
research study, conducted the experiments, analyzed the data, and wrote the manu-
script. M.M.R. designed the research study, analyzed the data, and wrote the manu-
script. All authors commented on and approved the ﬁnal manuscript.
We thank Maibritt Sigvardt Baggesen for skillful technical assistance.
We declare that we have no conﬂicts of interest with the contents of this article.
REFERENCES
1. Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.
2015. Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immu-
nol 391:355–381. https://doi.org/10.1007/978-3-319-22834-1_12.
2. Arfelt KN, Fares S, Rosenkilde MM. 2015. EBV, the human host, and the
7TM receptors: defense or offense? Prog Mol Biol Transl Sci 129:395–427.
https://doi.org/10.1016/bs.pmbts.2014.10.011.
3. Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y. 2018. Therapies based on
targeting Epstein-Barr virus lytic replication for EBV-associated malig-
nancies. Cancer Sci 109:2101–2108. https://doi.org/10.1111/cas.13634.
4. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral
infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol
25:587–617. https://doi.org/10.1146/annurev.immunol.25.022106.141553.
5. Becker Y, Tabor E, Asher Y. 1988. Differential expression of Epstein-Barr virus
(EBV) genes BBRF3, BILF1, and BMRF2 in EBV-transformed lymphoblastoid
lines from ataxia-telangiectasia patients. Leukemia 2:178S–191S.
6. Nakayama T, Fujisawa R, Izawa D, Hieshima K, Takada K, Yoshie O. 2002.
Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and
CCR10 and downregulate CXCR4 and CXCR5. J Virol 76:3072–3077.
https://doi.org/10.1128/JVI.76.6.3072-3077.2002.
7. Ehlin-Henriksson B, Liang W, Cagigi A, Mowaﬁ F, Klein G, Nilsson A. 2009.
Changes in chemokines and chemokine receptor expression on tonsillar
B cells upon Epstein-Barr virus infection. Immunology 127:549–557.
https://doi.org/10.1111/j.1365-2567.2008.03029.x.
8. Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD,
Rowe M. 2014. Cooperation between Epstein-Barr virus immune evasion
proteins spreads protection from CD8 T cell recognition across all
three phases of the lytic cycle. PLoS Pathog 10:e1004322. https://doi
.org/10.1371/journal.ppat.1004322.
9. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. 2012. The
EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells
from immune recognition and elimination. PLoS Pathog 8:e1002704.
https://doi.org/10.1371/journal.ppat.1002704.
EBV-BILF1 Extracellular Domains ®
January/February 2019 Volume 10 Issue 1 e01707-18 mbio.asm.org 13
 o
n
 M
arch 5, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
10. Rosenkilde MM, Waldhoer M, Luttichau HR, Schwartz TW. 2001. Virally
encoded 7TM receptors. Oncogene 20:1582–1593. https://doi.org/10
.1038/sj.onc.1204191.
11. Rosenkilde MM, Kledal TN. 2006. Targeting herpesvirus reliance of the
chemokine system. Curr Drug Targets 7:103–118.
12. Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, Holst B,
Ciﬁre F, Lipp M, Schwartz TW, Lira SA. 2001. Tumorigenesis induced by
the HHV8-encoded chemokine receptor requires ligand modulation of
high constitutive activity. J Clin Invest 108:1789–1796. https://doi.org/
10.1172/JCI13622.
13. Spiess K, Jeppesen MG, Malmgaard-Clausen M, Krzywkowski K, Kledal
TN, Rosenkilde MM. 2017. Novel chemokine-based immunotoxins for
potent and selective targeting of cytomegalovirus infected cells. J Im-
munol Res 2017:4069260. https://doi.org/10.1155/2017/4069260.
14. Lyngaa R, Norregaard K, Kristensen M, Kubale V, Rosenkilde MM, Kledal
TN. 2010. Cell transformation mediated by the Epstein-Barr virus G
protein-coupled receptor BILF1 is dependent on constitutive signaling.
Oncogene 29:4388–4398. https://doi.org/10.1038/onc.2010.173.
15. Grifﬁn BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F,
Ressing ME, Wiertz E. 2013. EBV BILF1 evolved to downregulate cell
surface display of a wide range of HLA class I molecules through their
cytoplasmic tail. J Immunol 190:1672–1684. https://doi.org/10.4049/
jimmunol.1102462.
16. Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop
AD, Rowe M. 2011. The Epstein-Barr virus-encoded BILF1 protein mod-
ulates immune recognition of endogenously processed antigen by tar-
geting major histocompatibility complex class I molecules trafﬁcking on
both the exocytic and endocytic pathways. J Virol 85:1604–1614. https://
doi.org/10.1128/JVI.01608-10.
17. Zuo J, Currin A, Grifﬁn BD, Shannon-Lowe C, Thomas WA, Ressing ME,
Wiertz EJ, Rowe M. 2009. The Epstein-Barr virus G-protein-coupled re-
ceptor contributes to immune evasion by targeting MHC class I mole-
cules for degradation. PLoS Pathog 5:e1000255. https://doi.org/10.1371/
journal.ppat.1000255.
18. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN. 2005. Epstein-Barr
virus-encoded BILF1 is a constitutively active G protein-coupled recep-
tor. J Virol 79:536–546. https://doi.org/10.1128/JVI.79.1.536-546.2005.
19. Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, Leurs R,
Bruggeman CA, Vink C. 2005. The Epstein-Barr virus BILF1 gene encodes
a G protein-coupled receptor that inhibits phosphorylation of RNA-
dependent protein kinase. J Virol 79:441–449. https://doi.org/10.1128/
JVI.79.1.441-449.2005.
20. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, Leurs R, Smit
MJ. 2001. Constitutive signaling of the human cytomegalovirus-encoded
chemokine receptor US28. J Biol Chem 276:1133–1137. https://doi.org/
10.1074/jbc.M008965200.
21. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, Michel
D, van Dongen GA, Smit MJ. 2006. Human cytomegalovirus-encoded
chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci
U S A 103:13068–13073. https://doi.org/10.1073/pnas.0604433103.
22. Holst PJ, Luttichau HR, Schwartz TW, Rosenkilde MM. 2003. Virally en-
coded chemokines and chemokine receptors in the role of viral infec-
tions. Contrib Microbiol 10:232–252.
23. Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M. 2015.
Unexpected patterns of Epstein-Barr virus transcription revealed by a
high throughput PCR array for absolute quantiﬁcation of viral mRNA.
Virology 474:117–130. https://doi.org/10.1016/j.virol.2014.10.030.
24. Spiess K, Fares S, Sparre-Ulrich AH, Hilgenberg E, Jarvis MA, Ehlers B,
Rosenkilde MM. 2015. Identiﬁcation and functional comparison of seven-
transmembrane G-protein-coupled BILF1 receptors in recently discov-
ered nonhuman primate lymphocryptoviruses. J Virol 89:2253–2267.
https://doi.org/10.1128/JVI.02716-14.
25. Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE.
2017. Trends in GPCR drug discovery: new agents, targets and indica-
tions. Nat Rev Drug Discov 12:829–842. https://doi.org/10.1038/nrd
.2017.178.
26. Elling CE, Nielsen SM, Schwartz TW. 1995. Conversion of antagonist-
binding site to metal-ion site in the tachykinin NK-1 receptor. Nature
374:74–77. https://doi.org/10.1038/374074a0.
27. Elling CE, Thirstrup K, Holst B, Schwartz TW. 1999. Conversion of agonist
site to metal-ion chelator site in the beta(2)-adrenergic receptor. Proc
Natl Acad Sci U S A 96:12322–12327.
28. Holst B, Elling CE, Schwartz TW. 2002. Metal ion-mediated agonism and
agonist enhancement in melanocortin MC1 and MC4 receptors. J Biol
Chem 277:47662–47670. https://doi.org/10.1074/jbc.M202103200.
29. Rosenkilde MM, Lucibello M, Holst B, Schwartz TW. 1998. Natural agonist
enhancing bis-His zinc-site in transmembrane segment V of the tachy-
kinin NK3 receptor. FEBS Lett 439:35–40.
30. Rosenkilde MM, Andersen MB, Nygaard R, Frimurer TM, Schwartz TW.
2007. Activation of the CXCR3 chemokine receptor through anchoring of
a small molecule chelator ligand between TM-III, -IV, and -VI. Mol
Pharmacol 71:930–941. https://doi.org/10.1124/mol.106.030031.
31. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW. 1999.
Agonists and inverse agonists for the herpesvirus 8-encoded constitu-
tively active seven-transmembrane oncogene product, ORF-74. J Biol
Chem 274:956–961.
32. Thiele S, Steen A, Jensen PC, Mokrosinski J, Frimurer TM, Rosenkilde MM.
2011. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a
chimeric receptor approach. J Biol Chem 286:37543–37554. https://doi
.org/10.1074/jbc.M111.243808.
33. Barington L, Rummel PC, Luckmann M, Pihl H, Larsen O, Daugvilaite V,
Johnsen AH, Frimurer TM, Karlshoj S, Rosenkilde MM. 2016. Role of
conserved disulﬁde bridges and aromatic residues in extracellular
loop 2 of chemokine receptor CCR8 for chemokine and small mole-
cule binding. J Biol Chem 291:16208–16220. https://doi.org/10.1074/
jbc.M115.706747.
34. Karlshoj S, Amarandi RM, Larsen O, Daugvilaite V, Steen A, Brvar M, Pui
A, Frimurer TM, Ulven T, Rosenkilde MM. 2016. Molecular mechanism of
action for allosteric modulators and agonists in CC-chemokine receptor
5 (CCR5). J Biol Chem 291:26860–26874. https://doi.org/10.1074/jbc
.M116.740183.
35. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le
Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. 2000.
Crystal structure of rhodopsin: a G protein-coupled receptor. Science
289:739–745.
36. Grundmann M, Merten N, Malfacini D, Inoue A, Preis P, Simon K, Ruttiger
N, Ziegler N, Benkel T, Schmitt NK, Ishida S, Muller I, Reher R, Kawakami
K, Inoue A, Rick U, Kuhl T, Imhof D, Aoki J, Konig GM, Hoffmann C,
Gomeza J, Wess J, Kostenis E. 2018. Lack of beta-arrestin signaling in the
absence of active G proteins. Nat Commun 9:341. https://doi.org/10
.1038/s41467-017-02661-3.
37. Liebscher I, Schon J, Petersen SC, Fischer L, Auerbach N, Demberg LM,
Mogha A, Coster M, Simon KU, Rothemund S, Monk KR, Schoneberg T.
2014. A tethered agonist within the ectodomain activates the adhesion
G protein-coupled receptors GPR126 and GPR133. Cell Rep 9:2018–2026.
https://doi.org/10.1016/j.celrep.2014.11.036.
38. Niss AK, Fares S, Sparre-Ulrich AH, Hjorto GM, Gasbjerg LS, Molleskov-
Jensen AS, Benned-Jensen T, Rosenkilde MM. 2017. Signaling via G
proteins mediates tumorigenic effects of GPR87. Cell Signal 30:9–18.
https://doi.org/10.1016/j.cellsig.2016.11.009.
39. Nevins AM, Marchese A. 2018. Detecting cell surface expression of the G
protein-coupled receptor CXCR4. Methods Mol Biol 1722:151–164.
https://doi.org/10.1007/978-1-4939-7553-2_10.
40. Ballesteros JA, Weinstein H. 1995. Integrated methods for the construc-
tion of three-dimensional models and computational probing of
structure-function relations in G protein-coupled receptors, p 366–428.
In Sealfon SC (ed), Receptor molecular biology. Academic Press, New
York, NY.
41. Katritch V, Cherezov V, Stevens RC. 2012. Diversity and modularity of G
protein-coupled receptor structures. Trends Pharmacol Sci 33:17–27.
https://doi.org/10.1016/j.tips.2011.09.003.
42. Katritch V, Cherezov V, Stevens RC. 2013. Structure-function of the G
protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:
531–556. https://doi.org/10.1146/annurev-pharmtox-032112-135923.
43. Rummel PC, Thiele S, Hansen LS, Petersen TP, Sparre-Ulrich AH, Ulven T,
Rosenkilde MM. 2013. Extracellular disulﬁde bridges serve different pur-
poses in two homologous chemokine receptors, CCR1 and CCR5. Mol
Pharmacol 84:335–345. https://doi.org/10.1124/mol.113.086702.
44. Peeters MC, van Westen GJ, Li Q, IJzerman AP. 2011. Importance of the
extracellular loops in G protein-coupled receptors for ligand recognition
and receptor activation. Trends Pharmacol Sci 32:35–42. https://doi.org/
10.1016/j.tips.2010.10.001.
45. Storjohann L, Holst B, Schwartz TW. 2008. Molecular mechanism of
Zn2 agonism in the extracellular domain of GPR39. FEBS Lett 582:
2583–2588. https://doi.org/10.1016/j.febslet.2008.06.030.
46. Davidson FF, Loewen PC, Khorana HG. 1994. Structure and function in
rhodopsin: replacement by alanine of cysteine residues 110 and 187, com-
Fares et al. ®
January/February 2019 Volume 10 Issue 1 e01707-18 mbio.asm.org 14
 o
n
 M
arch 5, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
ponents of a conserved disulﬁde bond in rhodopsin, affects the light-
activated metarhodopsin II state. Proc Natl Acad Sci U S A 91:4029–4033.
47. Perlman JH, Wang W, Nussenzveig DR, Gershengorn MC. 1995. A disul-
ﬁde bond between conserved extracellular cysteines in the thyrotropin-
releasing hormone receptor is critical for binding. J Biol Chem 270:
24682–24685. https://doi.org/10.1074/jbc.270.42.24682.
48. Chabot DJ, Zhang PF, Quinnan GV, Broder CC. 1999. Mutagenesis of CXCR4
identiﬁes important domains for human immunodeﬁciency virus type 1 X4
isolate envelope-mediated membrane fusion and virus entry and reveals
cryptic coreceptor activity for R5 isolates. J Virol 73:6598–6609.
49. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun
A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC.
2010. Structures of the CXCR4 chemokine GPCR with small-molecule and
cyclic peptide antagonists. Science 330:1066–1071. https://doi.org/10
.1126/science.1194396.
50. Zhang J, He S, Wang Y, Brulois K, Lan K, Jung JU, Feng P. 2015.
Herpesviral G protein-coupled receptors activate NFAT to induce tumor
formation via inhibiting the SERCA calcium ATPase. PLoS Pathog 11:
e1004768. https://doi.org/10.1371/journal.ppat.1004768.
51. Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare
KJ, Poulsen SS. 2012. Glucagon-like peptide-1 (GLP-1) receptor agonism
or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated
mice. Regul Pept 179:91–100. https://doi.org/10.1016/j.regpep.2012.08
.016.
52. Kostenis E, Martini L, Ellis J, Waldhoer M, Heydorn A, Rosenkilde MM,
Norregaard PK, Jorgensen R, Whistler JL, Milligan G. 2004. A highly
conserved glycine within linker I and the extreme C terminus of G
protein alpha subunits interact cooperatively in switching G protein-
coupled receptor-to-effector speciﬁcity. J Pharmacol Exp Ther 313:
78–87. https://doi.org/10.1124/jpet.104.080424.
EBV-BILF1 Extracellular Domains ®
January/February 2019 Volume 10 Issue 1 e01707-18 mbio.asm.org 15
 o
n
 M
arch 5, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
